Trial Profile

A Phase 2 Trial of SRF617 in Combination With AB928 (Etrumadenant) and AB122 (Zimberelimab) in Patients With Metastatic Castration-Resistant Prostate Cancer

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 22 May 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Etrumadenant (Primary) ; SRF 617 (Primary) ; Zimberelimab (Primary)
Indications Prostate cancer
Focus Adverse reactions; Therapeutic Use
Sponsors Coherus Biosciences; Surface Oncology

Most Recent Events

11 Apr 2023 Status changed from active, no longer recruiting to completed.
28 Nov 2022 Planned End Date changed from 1 Nov 2023 to 1 Jul 2023.
28 Nov 2022 Planned primary completion date changed from 1 Nov 2023 to 1 May 2023.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com